	UCSF IACUC Full Committee Meeting Minutes
Committee Name:	IACUC Full Committee
Committee Type:	IACUC
Meeting Date:	06/04/2019
Chair's Report:	Voting Members:
	Office Staff:
	Office Staff:
	IACUC Chair's Report
	(LC)
	A. Minutes
	a. 4/30/2019 Policy Minutes (Handout)- Minutes from 4/30 Policy Meeting were approved b. 5/7/2019 Full Committee Minutes (Handout)- Minutes from 5/7 Full committee were approved
Director's Report:	IACUC Director's Report
	A. Director's Report (Handout)
	Job postings: The position of IACUC Director is now posted and search committee named. day at UCSF is June 27. I eft LARC and is now at the second search committee named. LARC has posted a position for a Veterinarian level II. Hunters Point is working to hire a second veterinarian for their program (along with a total of four vet techs).
	IACUC Chair: is the June 4 meeting
	Tropical Rat Mites: LARC will be presenting an update on the Tropical Rat Mite situation that started with Parnassus rodents (non USDA). Pending some additional information, we will follow up on our initial informal report to NIH-OLAW.
	Surgery training and oversight: Program Review as well as the 5/7/19 IACUC meetings discussed surgery outcomes. The 5/7/19 Committee requested a report on surgical complication rates and info on the training resources that would be necessary to have hands-on surgery/anesthesia training for all researchers (we'll need to fine-tune that request everyone go through the very basic IACUC/LARC training courses AND in-lab training with a certified trainer for the specific procedures?) presented on this at the 5/21 meeting, and will do so at the June 4 meeting as well.
	A Program Review Subcommittee met on May 3 and will provide a summary for IACUC member review and signature at the 5/21 and June 4 meetings.
	June inspections are coming! But relax, we do not need members to sign up for anything. These are semi-formal inspections that the IACUC staff, as a single annual inspection of low-risk spaces (mostly, in-lab terminal perfusions) and a 3rd inspection to supplement our two official semi-annual IACUC inspections of higher-risk sites (USDA species; Lab housing; Chambers; in-lab Survival Surgery). Hunters Point is no longer on the high-risk list.

NOTES from some recent meetings:

From the May 21, 2019 meeting:

Brief LARC update that some rodent rooms at Parnassus are still under quarantine for **Ornithonyssus Tropical Rat Mites** 

	Explained why <b>Explained why measure and the submittee after it was reviewed by FCR on April 16 and May 21.</b> The April 16 review granted a one-month approval on May 10, to expire on June 10. The Committee reviewed the Continuation protocol (submitted on May 20) on May 21. The Committee did not find the submitted article on multimodal analgesia in human patients on patient-controlled morphine a compelling case against multimodal analgesia for nonhuman primates on buprenorphine.
	June 4, 2019 Subcommittee:
	Reviewed <b>provide</b> pilot report on animals with Wernicke's disease, housed in various oxygen (hypoxia to hyperoxia) environments. Hypoxia seems to improve some conditions, but setting endpoints for the model is challenging.
	Informed Committee that the June 4 DMR Subcommittee had reviewed a progress report on a PI's work developing a mouse model of Wernicke's disease. The initial report found insufficient MRI or histopathological change when mice go to 30% weight loss, but did not collect sufficient data at 40% weight loss to justify that endpoint for further expanded studies. PI will be allowed to conduct another smaller pilot study to assess whether animals at 40% weight loss show the lesions, and to explain better why it is necessary to see lesions when time-to-illness is already established.
Attending Veterinarian	AV Report/LARC Clinical Case Report
(AV) Report:	A. Tropical Rat Mites Report and Update (Handout)
	LARC Director/AV updated the Committee on infestation of tropical rat mites in the mouse/rat rooms at PSB. <b>Sector Constitution</b> will coordinate fact-finding on the extent of the effects (if any) on NIH-funded reports, the causes of any problems, and IACUC/LARC improvements to minimize future such situations. NIH-OLAW received an initial phone call, and will expect a written follow-up if investigators report significant disruption to funded projects.
IACUC Member Training	Committee Information and Training

and Information:

Α.

Presentation - Surgery Training Updates- Deferred to next Parnassus meeting

Β. considerations- Deferred to next meeting - Cephalopods & Animal Welfare

C. Upcoming CE opportunities:

• June 20, 2019: PRIM&R Webinar Advanced Noncompliance Scenarios https://www.primr.org/calendar/webinars/2019/noncompliance-scenarios/

August 23, 2019: NCB AALAS Educational Symposium

• 2019 SCAW IACUC Training Workshop: https://scaw.com/iacuc-training-workshops/

o September 27, 2019: New York City, NY

o November 22, 2019: Chicago, IL

• 2019 IACUC 101 Series: https://iacuc101.org/courses/iacuc-101/

o June 26 - 27, 2019: IACUC 101 and 301 in Providence, RI - Hosted by Brown University

o August 21 - 22, 2019: IACUC 101 and 201 in Minneapolis, MN - Hosted by Medtronics

o November 6, 7, 8, 2019: IACUC 101, 201 and 301 in Houston, TX - Hosted by Rice University

Other Business: • Other Business

A. Standard Procedures for DMR June 2019 List (Handout)- Deferred to next meeting

Committee continued discussion of veterinarians at other universities, including two primate centers, finding that multimodal analgesia is a widespread standard of care for laboratory primates undergoing similar surgeries. Committee weighed concerns about hemostasis for surgeries that penetrate the dura and those that do not. Committee voted for DMR-following-FCR if the vice-chair ( reviews that the PI has complied with all the requested revisions, and FCR if not. Committee's letter (details below) will include instructions on required animal care (and no allowed data collection) if the protocol expires. Vote: 11 in favor, 1 abstention.

Semi-annual Program Review : Members received the documents in advance of the meeting and signed the letter to the IO. Committee leadership plus the AV will present the semi-annual program review to the IO in June.

Deferred agenda items: Committee CE on cephalopods in laboratories. Review of the surgery training and oversight program (requested update from the Program Evaluation in May, and presented once already at the May 21 meeting).

#### **Protocols Reviewed**

During the review process, the members discussed for each protocol, the rationale for involving animals, the appropriateness of the species, the database searches for alternatives, the steps taken to reduce animal numbers, the measures to relieve pain, discomfort or distress, if needed, the appropriateness and adequacy of anesthesia and analgesia, if applicable, and the number of animals to be used.

# **USDA Covered Species**

Project Number:

Approval Type: Annual Review

Title: Structural Basis of Amblyopia and Strabismus

PI:

Species: Macaque Monkey, Mouse, Rat

Primary Reviewer:

Secondary Reviewer:

#### **Results: Revisions Requested**

Revisions Section E.2.2. Explain why the proposed species are the most appropriate Requested: Please provide more detail on why mice versus rats would be used for particular pilot procedures. Explain the criteria you consider in deciding whether to acquire mice or rats for a given experiment. Section I. Analgesic Agents For the rodents:

o IACUC recommends using SR-buprenorphine rather than twice daily Buprenorphine HCI. It is acceptable to have both formulations in your protocol for flexibility. The UCSF dose of SR Buprenorphine is typically 1.5 mg/kg for mice.

o Add Meloxicam as an analgesic for mice and rats for all survival surgical procedures. o Additionally, lidocaine/bupivacaine is indicated for these surgeries as well and should be put back into the protocol.

#### For NHPs:

o For surgeries that do not penetrate the dura, under "Frequency & Total Duration" administer one dose of meloxicam at time of surgery,1-2x on the day after surgery, and after that, 1-2x/day as needed

o For surgeries that penetrate the dura, add acetaminophen suppository back into the analgesic agents for NHP, once at the time of the Procedure. For those surgeries either continue acetaminophen 3x/day for 1 day on the day after surgery, then as needed OR start meloxicam treatment on the day after surgery

Section J. Management and Monitoring of Adverse Effects of Procedures and Experimental Agents

#### Macaque:

Subsection J.2:

• -You should remove the statement: "Please note: We will document monitoring of animals after surgery...," You may change "Yes" to "..."Monitoring notes will cover clinically important information," if you prefer.

Mice and rats: Subsection J.3:

.


On your behalf, IACUC has added dehiscence repair as a Standard Procedure for mice and rats in Section F.

#### Documents


1. Please upload to the "Attachments" listing in RIO ("Documents" section), the version of campus "Guidelines for Food Regulation" and campus "Guidelines for Water Regulation" that you use. The protocol is not complete without these documents


2. By June 15 2019, it will be necessary for you to work with LARC's primate veterinarians to develop and upload an SOP for all hand-cleaned animal-related items used for your projects, including restraint chairs and slurry-delivery systems. This will assure your regimen addresses the USDA's concerns from the March inspection.

The SOP will need to set frequencies and methods of sanitization of hand-washed food and restraint equipment, frequencies of sanitization method verification (e.g., annual ATPase validation of your methods), and methods of fully cleaning equipment (e.g., removing all slurry residue after each use) in the days or weeks between sanitization procedures. Veterinarians will work with you to set documentation expectations. The USDA plans to inspect your laboratory and review your procedures in her fall 2019 inspection.



#### **Non-USDA Covered Species**





Section D. Personnel and Contacts

We have deleted from the protocol as his email address is no longer valid.

Section G. Procedures Involving Living Animals

• Category D: Please create a flow chart or table listing the number of animals (for each species) that will undergo the various procedures/combinations of procedures. This can be incorporated as a supplemental file that you can upload and include in the "Documents" section of RIO.

• Category D mice: "Agents administered through chow" and small paragraph following this phrase: Please clarify and re-write so that the reader understands: (1) exactly which agents (e.g. PLX5622 and/or additional agents?) will be administered through chow; and (2) whether hypoxia ischemia + analyses will be part of \*all\* listed procedures that follow?

# Project Number: Approval Type: New Approval Title: Characterizing the Innate Immune Response of Mycobacterium Tuberculosis with Single-Cell Resolution PI: Image: Plice Primary Reviewer: Species: Mouse Primary Reviewer: (1) Reviewer: Revisions Requested Revisions Revisions C. Animals

There seems to be a mathematical discrepancy between the total number of Category D. acquired in the summary able (289) and in the table at the bottom of your narrative (297).
In the table at the bottom of the narrative, please indicate which animals are bred vs acquired to help reviewers understand how your totals were calculated,

• Please provide a detailed statistical justification explaining your group sizes.

• You explain that females will not be used in experiments, as there are considerable gender differences in the immune response to MTB infection. However, the paper referenced does indeed include both genders (p.1) and clearly describes why both should be used. Therefore, the Committee strongly recommends using males and females and accounting for this variable in your statistical analysis.

Section G. Procedures

• Category Dr. mice infected with MTB: You state that the inhalation exposure device can accommodate up to 20 mice per compartment. However, in the attached biosafety manual, the device description states that no more than 10 mice per basket can be kept. Please reconcile both statements.

Section J. Adverse Effects

• Please separate the adverse effects listed (all pertaining to MTB exposure) into separate row/entries.

	UCSF IACUC Subcommittee Meeting Minutes
Committee Name:	IACUC SubCommittee/DMR
Committee Type:	IACUC
Meeting Date:	06/04/2019
Members Present:	IACUC Chair (or Vice Chair):
	LARC Attending Veterinarian or Designee:
	IACUC Committee Member as Specified:
Chair's Report:	Subcommittee: (via Zoom Conference Call)
	1. Subcommittee Minutes
	- 5/7/2019 Subcommittee Minutes (Handout)- Minutes from 5/7 Sub committee were approved
Training and Compliance Report:	2. Training & Compliance Report
Кероп.	- Pilot Data Summary (Handout)- Reviewed provide pilot report on animals with Wernicke's disease, housed in various oxygen (hypoxia to hyperoxia) environments. Hypoxia seems to improve some conditions, but setting endpoints for the model is challenging.

#### **Protocols Reviewed**

The following protocols will be reviewed by Designated Member Review process in accordance with the PHS Policy Section IV.B.3.

#### **USDA Covered Species**

Project Number: AN176202-02

Approval Type: Annual Review


Title: Holding Protocol for Animals Assigned to Inactive Protocols or Special Circumstances

PI:

Species: Bird, Cat, Dog, Ferret, Fish, Frog, Gerbil, Guinea Pig, Hamster, Macaque Monkey, Mouse, Rabbit, Rat, Salamander, Sheep, Squirrel Monkey, Swine, Vole, Zebrafish

# Results: Revisions Requested


Revisions Please provide, in the progress report, how many of each USDA-covered species were used Requested: over the past year.



Project Number:	
Approval Type:	Modification
Title:	Plasticity and Behavioral Coding in the Rodent Brain
PI:	
Species:	Rat
Results:	Approved
Project Number:	
Approval Type:	Modification
Title:	Post-transcriptional regulatory pathways that drive cancer metastasis
PI:	
Species:	Mouse
Results:	Revisions Requested
	-The Committee suggests scheduling a technical consultation with this company that may formulate these compounds directly in the feed. Please look at the link below for more information: https://www.researchdiets.com/
	-If gavage is necessary, please specify the vehicle used (in Section I.)
	-No changes were done to your total of animal numbers. Could you clarify whether new mice will be used? How many will be treated with the new compounds? Please make changes to Section C. if needed.
Project Number:	
Approval Type:	Modification
	In Vivo Evaluation of Experimental Anti-Cancer Therapeutics; UCSF Preclinical Therapeutics Core
PI:	
-	Mouse, Rat
Results:	Approved
Project Number:	
-	Annual Review/Modify
Title:	Circuit and functional organization of the rodent auditory system
PI:	
Species:	Mouse
-	Approved

Project Number: Approval Type: Modification Title: Transcriptional control of adipocyte development and energy metabolism PI: Species: Mouse Results: Revisions Requested Revisions In Section C., please provide additional information on your group size calculation and include Requested: effect size/variance. Project Number: Approval Type: Annual Review Title: The Function of Immune Surveillance in Peripheral Organs and Tissues: Anti-tumor mechanisms of intratumoral stimulatory dendritic cells; IL-13 and IL-17 dynamics in the asthmatic airway; Manipulating Collectivity and Niches for Developing CD8 Immunity; Mechanisms of peripheral self-tolerance contribute to immune tolerance to cancer; Interrogation of immune responses to fibrolamellar hepatocellular carcinoma; Reinvigorating anti-tumor immunity by reversing macrophage-induced T cell dysfunction; Integrating targeted and immunotherapy to treat genetically heterogeneous cancers; Living Tumor Biopsies to Interrogate Immune Function and Response to Therapy PI: Species: Mouse Results: Approved Project Number: Approval Type: Annual Review Title: Epigenetic regulation of brain tumors PI: Species: Mouse Results: Approved Project Number: Approval Type: Annual Review Title: The in vivo roles of a ciliogenesis-regulating kinases ICK (Intestinal Cell Kinase) during the embryonic development of the small intestine PI: Species: Mouse Results: Approved

Project Number:	
Approval Type:	Annual Review/Modify
Title:	Gladstone Behavioral Assessment Unit
PI:	
Species:	Mouse
Results:	Approved
Project Number:	
-	
Approval Type:	Modification
Title:	Genetic Approaches To Understanding Ocular Diseases
PI:	
Species:	Mouse
Results:	Revisions Requested
	Add local block (in Section I.) to the anesthetics/analgesics regimen for your mice undergoing the "head mounted goggle" procedure.
	Please schedule a procedure observation of the first cohort of mice undergoing the new
Requirements:	procedure "head mounted goggle surgery". Pleas email



	<b>UCSF IACUC Full Committee Meeting Minutes</b>
Committee Name:	IACUC Full Committee
Committee Type:	IACUC
Meeting Date:	06/18/2019
Chair's Report:	Voting Members:
	Office Staff:
	Guests:
	IACUC Chair's Report
	A. Minutes a. 5/21/2019 Full Committee Minutes (Handout)- Minutes from 5/21 Full committee were approved
Director's Report:	IACUC Director's Report
	• IACUC Director informed Committee that will be interim director for the IACUP office when (June 27)
	• Informational: Tropical Rat Mites: <b>Exercises</b> is heading up some work with LARC to identify impacts of Tropical Rat Mites on mouse and rat research projects. Pending some additional information, we will follow up on our initial informal report to NIH-OLAW.
	• Informational: Subcommittee met with mouse Planet to review her pilot findings for her Wernicke Disease model. Agreed that another pilot, with 90 animals, would be appropriate to further refine the model before proceeding to more expansive studies.
	• Informational: Director updated the Committee on primate protocol. Protocol was reviewed in Full Committee in April and twice in May. A one-month approval granted in May has expired as of June 10. The PI has not resubmitted. The animals are on LARC's Holding Protocol with LARC veterinarians directing their care, and the PIs staff are required to provide specialized implant maintenance. NIH-OLAW has been informed (no non-compliances, so just a courtesy note to OLAW), as have been the PI's department. The UCSF Office of Sponsored Research, the IO, and the funding agency.
	Committee member asked how USDA will review this. Director opined that the USDA expects the IACUC to make its own decisions and respects that, but will also look if the IACUC changes its standards on whether that change is based on established veterinary practice and/or science.
Attending Veterinarian	AV Report/LARC Clinical Case Report
(AV) Report:	A. Tropical Rat Mites Report and Update
	updated Committee on tropical rat mite outbreak centered in PSB facility.
	<ul> <li>Initial source - most likely wild rodents in interstitial building space</li> <li>Contributing causes - lack of coordination among 3 pest control companies (1 for inside building, 1 for outside building, 1 for animal facility), rainy weather, nearby construction</li> <li>Control measures - doubled number of rodent bait stations and added more effective bait, cleaned and rodent-proofed interstitial spaces in PSB, rooms quarantined when mites are detected</li> <li>Treatment - permethrin nestlets placed in cages in quarantine rooms in PSB, Animal</li> </ul>

	<ul> <li>Towers; Rock Hall treatment is complete (1 room)</li> <li>Challenges – Backorder of commercial permethrin nestlets so LARC staff are making them; currently insufficient supply to treat all of PSB at once</li> <li>Surveillance - All rooms in PSB have now been tested by PCR; Genentech Hall, SFGH, Neurosciences also screened</li> <li>Zoonotic potential – LARC sent some mites to be tested for human pathogens; all negative</li> <li>Cost estimate for university – unknown</li> </ul>
IACUC Member Training and Information:	Committee Information and Training
	A. Cephalopods & Animal Welfare considerations- deferred to later meeting due to time constraints
	B. Upcoming CE opportunities:
	<ul> <li>June 20, 2019: PRIM&amp;R Webinar Advanced Noncompliance Scenarios https://www.primr.org/calendar/webinars/2019/noncompliance-scenarios/</li> </ul>
	<ul> <li>July 16, 2019: AALAS Webinar Abnormal Repetitive Behaviours: Animal Welfare Significance https://www.aalas.org/store/meeting?productId=9407786</li> </ul>
	August 23, 2019: NCB AALAS Educational Symposium
	2019 SCAW IACUC Training Workshop: https://scaw.com/iacuc-training-workshops/
	o September 27, 2019: New York City, NY o November 22, 2019: Chicago, IL
	<ul> <li>2019 IACUC 101 Series: https://iacuc101.org/courses/iacuc-101/</li> </ul>
	o June 26 - 27, 2019: IACUC 101 and 301 in Providence, RI - Hosted by Brown University
	o August 21 - 22, 2019: IACUC 101 and 201 in Minneapolis, MN - Hosted by Medtronics
	o November 6, 7, 8, 2019: IACUC 101, 201 and 301 in Houston, TX - Hosted by Rice University
Other Business:	Other Business
	A. Standard Procedures for DMR June 2019 List (Handout)- A. Informational - Members received list of standard procedures due for renewal this month; will be sent out for DMR

#### **Protocols Reviewed**


During the review process, the members discussed for each protocol, the rationale for involving animals, the appropriateness of the species, the database searches for alternatives, the steps taken to reduce animal numbers, the measures to relieve pain, discomfort or distress, if needed, the appropriateness and adequacy of anesthesia and analgesia, if applicable, and the number of animals to be used.

#### **USDA Covered Species**

Project Number:

Approval Type: Continuation

Title: Understanding social attachment in development and disease; EDGE: Transforming the social




Revisions -In Section G., Category D. Voles, Acoustic Startle Testing:

Requested: -Clarify how often the very loud sounds are delivered and what the total duration of exposure at 130 db would be.

-In Section I., please add DREADDs and Clozapine to your list of Experimental Agents (if still planning on using them).

#### **Non-USDA Covered Species**



Update all literature searches (search dates and years covered)

Section G. Procedures Involving Living Animals

General: You will need to provide additional details so that the committee clearly understands each proposed procedure & to ensure that this section is consistent with Section C.

Specific:

• Exp 1: provide the names of the knockout strains described in Section C.

• Exp 2: specify the strain of transgenic mice used (ITGB8 BAC Tg mice)

• Exp 3: IACUC staff removed unclear sentence on your behalf: "Optimized tobacco exposure measure system, no longer need to measure to determine the effective level of tobacco smoke exposure."

• Exp 4: for genetic cell-type specific deletion models: discrepancy between description of tamoxifen dosing here and Section 1.5. Reconcile accordingly.

• Exp 8: Active induction of EAE:

o Some additional description about the induction (agents used, timing of injection) must be provided.

o Details about what will subsequently happen to the animals must be provided.

• Exp 11: provide a complete description of this experiment.

• Exp 12: Effects of AvB8 on primary tumor growth:

o All the descriptive sentences related to procedures in Section C must be moved here.

o Cell numbers injected must match details given in Section I.5

o "Immunomodulatory agents," must be specified here or the "(see section)" needs to be clarified.

o IACUC staff edited the following on your behalf: "(see humane endpoints in Section I)"

Section I. Pre-Anesthetics and Anesthetics, Neuromuscular Blocking Drugs, Therapeutics, Analgesics and Experimental Agents

• Incomplete Freund's – frequency column: "2 times at days at 3 and 6 wks" — ?? not clear. Revise accordingly.

• Avertin as primary anesthetic – needs justification.

IACUC staff has corrected the following on your behalf:

• Tamoxifen - dosing frequency needs to match Section G

- Ad-Cre-eGFP and Ad-eGFP are not mentioned elsewhere in protocol delete
- Monoclonal antibody against avb6 is not mentioned elsewhere in protocol delete
- IL17 neutralizing antibodies not mentioned elsewhere delete (also delete in J.1)
- Pentobarbital not mentioned elsewhere delete


Section J. Management and Monitoring of Adverse Effects of Procedures and Experimental Agents

• IACUC staff has deleted the following on your behalf, as they do not appear anywhere else in protocol:

• ALK +/-; itgb8F/F

- CD11cYFP Col-cre;itgb8F/F
- mt/mG; cd11cYFP col-are itgb8 F/F
- PDGF cre-ER; TGFbr2 F/F
- NG2cre ERT; TGFbr2 F/F
- TCRa -/-

- 30% weight loss for influenza mice – specify the # of animals that lost >20% of weight, how long it took them to recover and how many recovered. Please provide this information in the response to this letter.



Revisions Section C. Animals

Requested: Category C:

• There appears to be a discrepancy between the number of Category C animals in the supplemental spreadsheet (total = 1980) and section C.1 (total = 5089). Please rectify.

Section E. Justifications and Alternatives

Section E.2.4: this section will need to be re-written, please. See comments below: • Re-organize this section such that you provide information for each of the 2 types of metastases: (1) surgical resection and (2) late-stage primary tumor.

• For each group (surgical resection animals, late-stage primary tumor animals):

o Specify the expected signs of pain and distress.

o Clarify which animals do/do not receive multimodal analgesia for surgery.

• For any animals that could die despite intensive monitoring (e.g. those that may expire from bladder obstruction caused by the primary cancer), provide the expected percentage mortality. Also, discuss what critical scientific data could be lost by euthanizing animals earlier in the disease process.


• Please provide justification for allowing tumors to reach 2.5cm.


• Also, clarify justification for not providing analgesics and/or anesthetics and clearly specify the procedures/groups in which those agents will not be administered.

	<b>UCSF IACUC Subcommittee Meeting Minutes</b>
Committee Name:	IACUC SubCommittee/DMR
Committee Type:	IACUC
Meeting Date:	06/18/2019
Members Present:	IACUC Chair (or Vice Chair):
	LARC Attending Veterinarian or Designee:
	IACUC Committee Member as Specified:
Chair's Report:	1. Subcommittee Minutes
	- 5/21/2019 Subcommittee Minutes (Handout)- Minutes from 5/21 subcommittee were approved
Training and Compliance Report:	2. Training & Compliance Report
	- Guest: <b>Here and Pilot</b> Data Summary (Handout)- Guest: <b>Here and Pilot</b> presented results of her pilot study investigating effects of hypoxia/hyperoxia on a mouse model of Wernicke's disease (thiamine deficiency)
	- Report- BB (Handout)- Laboration and Self report (Protocol Laboratory space not approved for ABSL2 animal housing and not listed on their IACUC protocol. Lab did not document daily checks of lab housed animals or contact IACUC at time of pilot study, as detailed in post-approval requirements of protocol. Subcommittee reviewed lab's corrective actions – met with IACUC, LARC, EHS, facility management to identify appropriate animal housing space and establish all required documentation. Voted to send acknowledgement letter, requiring progress report from next cohort of animals, and for lab members to complete overdue training.
Other Business:	3. Protocol Review Add-ons:
	- PI Transfer, (Handout)- Approved


# **Protocols Reviewed**

The following protocols will be reviewed by Designated Member Review process in accordance with the PHS Policy Section IV.B.3.





Project Number: Approval Type: Annual Review/Modify Title: In Vivo Evaluation of Experimental Anti-Cancer Treatment with Engineered T cells. PI: Species: Mouse Results: Revisions Requested Revisions Progress Report: Requested: Please provide an answer to the second question- on the health and welfare of Category E. mice. Section G. Procedures Involving Living Animals • Experiment 14: The Committee recommends using the lowest possible dose during the pilot experiment. Please contact the IACUC office via email or prior to beginning the LPS administration. • Experiment 15: Please provide additional information about the timeline of PLX feeding experiments. • Experiment 16: Please describe in details the monitoring regimen in place for the GSI experiment. Body weight loss of >15% needs to be justified and these mice must be placed in Category E. Please adjust your total of animal numbers in Section C. accordingly. Section J. Management and Monitoring of Adverse Effects of Procedures and Experimental Agents Please uncheck 15% weight loss as a humane endpoint, assuming that mice will be maintained up to 20% weight loss. Project Number: Approval Type: Modification Title: Characterizing and Targeting Tumor Factors Responsible for Vascularization and Recurrence of Glioblastoma PI: Species: Mouse Results: Approved Project Number: Approval Type: Annual Review/Modify Title: Cellular Dynamics and Interactions in IgE Responses and Asthma PI: Species: Mouse Results: Approved Project Number: Approval Type: Modification Title: Control of skeletal cell differentiation, matrix quality and hearing loss. PI: Species: Mouse Results: Approved



Project Number:	
Approval Type:	Annual Review
Title:	Cellular basis of retinal degenerative diseases
PI:	
Species:	Mouse
Results:	Approved
Project Number:	
Approval Type:	Modification
Title:	Lung Transplantation Studies in Mice
PI:	
Species:	Mouse
Results:	Approved
Post-Approval Requirements:	Please schedule a veterinary observation of the new spleen transplant procedure
Project Number:	
Approval Type:	Modification
	Activation of endogenous stem cells and the myogenic effects of LESW and CRISPRi for improvement of Obesity-Associated Stress Urinary Incontinence in the Zucker rat model.
PI:	
Species:	
Results.	Approved
Project Number:	
Approval Type:	Annual Review
Title:	Developmental signaling pathways in cancer
PI:	
Species:	Mouse
Results:	Approved
Project Number:	
Approval Type:	Modification
Title:	Use of Mouse and Rat Models for Cardiac Development and Regeneration Research
PI:	
Species:	Mouse, Rat
	Approved

Project Number:

Approval Type: Annual Review/Modify

Title: Analysis of HIV Infection in Humanized Mice

PI:

Species: Mouse


Results: Approved


	UCSF IACUC Subcommittee Meeting Minutes
Committee Name:	IACUC SubCommittee/DMR
Committee Type:	IACUC
Meeting Date:	06/26/2019
Members Present:	IACUC Chair (or Vice Chair):
	LARC Attending Veterinarian or Designee:
	IACUC Committee Member as Specified:
Training and Compliance Report:	1. Training & Compliance Report
	• noncompliance – LARC/IACUC observed rats left not fully recovered from anesthesia in a procedure room. Lab member performed surgical procedure (intracranial injection) without shaving or documenting analgesics. All lab members re-read the protocol, attended aseptic technique/surgery refresher training with attend July hands-on surgery training course. Subcommittee voted to send a warning letter, requiring follow up with PASSR next month, and weekly IACUC office review of surgery records/outcomes for next 3 months.
	• <b>Matrix and Construction</b> noncompliance – LARC observed mice improperly euthanized, and discovered that lab member <b>Matrix</b> was not performing a secondary method as described in IACUC protocol. Two lab members also performed rodent identification procedures not approved in IACUC protocol. Subcommittee voted to send a warning letter, requiring involved lab members to re-train in euthanasia and genotyping with IACUC staff. IACUC staff will also observe lab members next time they euthanize or genotype mice for study.

# **Protocols Reviewed**

The following protocols will be reviewed by Designated Member Review process in accordance with the PHS Policy Section IV.B.3.

# **USDA Covered Species**





Project Number:	
Approval Type:	Annual Review
Title:	Study of Kryptolebias marmoratus
PI:	
Species:	Fish
Results:	Approved
Project Number:	
Approval Type:	Annual Review/Modify
	Glioma Immunotherapy in Sleeping Beauty Transposon-Mediated De Novo Gliomas and other models
PI:	
Species:	Mouse
Results:	Revisions Requested
	As you are proposing to perform gavage on an extended period of time, we suggest first consulting with a company such as Bio-serv to see if they can formulate your new agent into chow. As an alternative, could you reduce the gavage period as you mentioned that the expected survival is about 35 days?
Project Number:	
Approval Type:	Modification
Title:	Pharmacological Validation of IRE1 $\alpha$ for Diabetes Mellitus
PI:	
Species:	Mouse
Results:	Revisions Requested
	There seems to be a discrepancy between the number of added mice in the table (200) vs what is described in the narrative (192).
Project Number:	
Approval Type:	Annual Review
Title:	The role of developmental pathways in regulating adult lung homeostasis and injury repair
PI:	
PI: Species:	

Project Number:       Image: Approval Type: Annual Review/Modify         Title:       Cell migration and lineage in the developing brain         P:       Image: Approved         Species:       Mouse         Results:       Approved         Project Number:       Image: Approved         Approval Type:       Annual Review         Title:       Mouse models to study uterine leiomyomas and infertility         Pi:       Image: Approved         Project Number:       Image: Approved         Species:       Mouse         Results:       Approved         Project Number:       Image: Approved         Project Number:       Image: Approved         Project Number:       Image: Approved         Species:       Mouse         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         Revisions:       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         Revisions:       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         Contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:       Image: Approved		
Title: Cell migration and lineage in the developing brain         Pi         Species: Mouse         Results: Approved         Project Number:         Approval Type: Annual Review         Title: Mouse models to study uterine leiomyomas and infertility         Pi:         Species: Mouse         Results: Approved         Pi:         Species: Mouse         Results: Approved         Project Number:         Species: Mouse         Results: Approved         Project Number:         Species: Mouse         Results: Approved         Project Number:         Species: Mouse         Results: Revisions Requested         Results: Revisions Requested         Revisions You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:         Approval Type: Annual Review         Title: Studies on Pancreatic Development, Disease, and Regeneration         Pi:         Species: Mouse	Project Number:	
PI:       Species: Mouse         Results:       Approved         Project Number:       Approval Type: Annual Review         Title:       Mouse models to study uterine leiomyomas and infertility         PI:       Species: Mouse         Species:       Mouse         Results:       Approved         Project Number:       Mouse         Approval Type:       Modification         Title:       GPR56 signaling in brain development, disease and injury         PI:       Species:         Species:       Mouse         Results:       Revisions         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:       Mouse         Approval Type:       Annual Review         Title:       Studies on Pancreatic Development, Disease, and Regeneration         PI:       Species:         Species:       Mouse	Approval Type:	Annual Review/Modify
Species:       Mouse         Results:       Approved         Project Number:	Title:	Cell migration and lineage in the developing brain
Results: Approved         Project Number:         Approval Type: Annual Review         Title: Mouse models to study uterine leiomyomas and infertility         Pi         Species: Mouse         Results: Approved         Project Number:         Approval Type: Modification         Title: GPR56 signaling in brain development, disease and injury         Pi:         Species: Mouse         Results: Revisions Requested         Revisions:       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:	PI:	
Project Number: Approval Type: Annual Review Title: Mouse models to study uterine leiomyomas and infertility PI: Species: Mouse Results: Approved Project Number: Approval Type: Modification Title: GPR56 signaling in brain development, disease and injury PI: Species: Mouse Results: Revisions Requested Revisions You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify? Project Number: Project Number: Project Number: Contradicts the power analysis you have in Section C. Could you please clarify? Project Number: Species: Mouse Mouse Project Number: Species: Mouse	Species:	Mouse
Approval Type: Annual Review Title: Mouse models to study uterine leiomyomas and infertility PI:	Results:	Approved
Title:       Mouse models to study uterine leiomyomas and infertility         Pl:       Species:         Species:       Mouse         Results:       Approved         Project Number:       Mouse         Approval Type:       Modification         Title:       GPR56 signaling in brain development, disease and injury         Pl:       Species:         Species:       Mouse         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:       Approval Type:         Approval Type:       Annual Review         Title:       Studies on Pancreatic Development, Disease, and Regeneration         Pl:       Species:         Species:       Mouse	Project Number:	
PI:       Species: Mouse         Results:       Approved         Project Number:       Species:         Approval Type:       Modification         Title:       GPR56 signaling in brain development, disease and injury         PI:       Species:         Species:       Mouse         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         Contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:       Approval Type:         Approval Type:       Annual Review         Title:       Studies on Pancreatic Development, Disease, and Regeneration         PI:       Species:         Species:       Mouse	Approval Type:	Annual Review
Species:       Mouse         Results:       Approved         Project Number:       Image: Comparison of the second o	Title:	Mouse models to study uterine leiomyomas and infertility
Results:       Approved         Project Number:	PI:	
Project Number: Approval Type: Modification Title: GPR56 signaling in brain development, disease and injury PI: Species: Mouse Results: <b>Revisions Requested</b> Revisions You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify? Project Number: Annual Review Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse	Species:	Mouse
Approval Type:       Modification         Title:       GPR56 signaling in brain development, disease and injury         Pl:       Pl:         Species:       Mouse         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:       Project Number:         Approval Type:       Annual Review         Title:       Studies on Pancreatic Development, Disease, and Regeneration         Pl:       Species:         Mouse       Species:	Results:	Approved
Title:       GPR56 signaling in brain development, disease and injury         PI:       Species:         Species:       Mouse         Results:       Revisions Requested         Revisions:       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested:         Project Number:	Project Number:	
PI:       Species: Mouse         Species: Mouse       Results: Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:	Approval Type:	Modification
Species:       Mouse         Results:       Revisions Requested         Revisions       You state that the EAE experiment will have a sample size of 5 and no replicates, which contradicts the power analysis you have in Section C. Could you please clarify?         Project Number:	Title:	GPR56 signaling in brain development, disease and injury
Results: Revisions Requested Revisions You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify? Project Number: Approval Type: Annual Review Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse	PI:	
Revisions You state that the EAE experiment will have a sample size of 5 and no replicates, which Requested: contradicts the power analysis you have in Section C. Could you please clarify?  Project Number: Approval Type: Annual Review Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse	Species:	Mouse
Requested: contradicts the power analysis you have in Section C. Could you please clarify? Project Number: Approval Type: Annual Review Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse	Results:	Revisions Requested
Approval Type: Annual Review Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse		
Title: Studies on Pancreatic Development, Disease, and Regeneration PI: Species: Mouse	Project Number:	
PI: Species: Mouse	Approval Type:	Annual Review
Species: Mouse	Title:	Studies on Pancreatic Development, Disease, and Regeneration
	PI:	
Results: Approved	Species:	Mouse
	Results:	Approved